ClinicalTrials.gg
CompletedNCT00735449Updated Apr 23, 2019Results posted

Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects

A Phase 4 interventional study of Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% and timolol maleate 0.5% in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-23.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing timolol in Glaucoma — none open to participants now, none under way, none of them phase 3. Timolol · Glaucoma.

Enrollment
4th of 28
204 · median 60
Started
2008
with 1 other
Phase 4
13 of 28
none open now
Registered
7th of 28
by date
Lead sponsor
4 of 28
Allergan

Among the 28 studies testing timolol in Glaucoma, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 13 in phase 4, and was the 7th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 28 studies testing timolol in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About timolol

Timolol: first FDA approval 1978 (TIMOPTIC), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 155 Glaucoma studies recruiting now, 113 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing timolol in Glaucoma as a file.
02

Study summary

Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive therapy to Xalatan in subjects with glaucoma or ocular hypertension.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years of age
  • Give written
  • Be in good general health as determined by your doctor
  • Have a diagnosis of unilateral or bilateral glaucoma or ocular hypertension
  • If you are a female of child bearing potential, you must be willing to practice effective for the duration of the study (i.e., abstinence, spermicide, condoms, or birth control pills)
  • Understand the study instructions, and be able to follow the study instructions; and
  • Be likely to complete the entire study period (12 weeks), including all regularly scheduled study visits

Exclusion criteria

Exclusion Criteria:

  • Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation
  • History of severe renal or hepatic impairment
  • Subjects with severe cardiovascular disease should not be enrolled unless their disease is controlled and clearance has been obtained from the subject's primary care physician and/or cardiologist
  • to beta-adrenoceptor antagonist therapy such as , bronchial asthma, sinus bradycardia, second and third degree atrioventricular block, overt cardiac failure and cardiogenic shock or uncontrolled congestive heart failure
  • Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results; and
  • Concurrent participation or prior participation in any drug or device study within the last 30 days prior to the screening visit
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
204 participants (actual)

Study arms

  • Active comparator
    Combigan ®

    Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%) adjunctive to Xalatan® (latanoprost 0.005%)

    Drug: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% · Drug: latanoprost 0.005%

  • Active comparator
    Timolol Maleate 0.5%

    Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)

    Drug: timolol maleate 0.5% · Drug: latanoprost 0.005%

Interventions

  • DrugFixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%

    1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.

    Also known as: Combigan®

  • 1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.

    Also known as: Timpoptic®, Timoptol®

  • 1 drop of latanoprost 0.005% once nightly.

    Also known as: Xalatan®

06

What researchers measure

Primary outcomes

  1. Mean Intraocular Pressure (IOP) at 10 AM at Week 12

    Mean IOP at 10 AM at week 12. IOP is a measurement of the fluid pressure in the eye.

    Time frame: Week 12

Secondary outcomes

  1. Mean Intraocular Pressure (IOP) at 10 AM at Week 6

    Mean IOP at 10 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.

    Time frame: Week 6

  2. Mean Intraocular Pressure (IOP) at 8 AM at Week 12

    Mean IOP at 8 AM at week 12. IOP is a measurement of the fluid pressure inside the eye.

    Time frame: Week 12

  3. Mean Intraocular Pressure (IOP) at 8 AM at Week 6

    Mean IOP at 8 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.

    Time frame: Week 6

  4. Number of Subjects With Adverse Events

    Number of subjects with adverse events, defined as any untoward medical occurrence in a subject, during the study (reported through the week 12 visit).

    Time frame: Week 12

07

Results

Posted Nov 24, 2011

Participant flow

Participant flow — Overall Study
MilestoneCombigan®Timolol Maleate 0.5%
Started102102
Completed9596
Not completed76

Outcome measures

SecondaryMean Intraocular Pressure (IOP) at 10 AM at Week 6

Mean IOP at 10 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.

Time frame:
Week 6
Reported as:
Mean · Millimeters of mercury (mmHg)
Mean Intraocular Pressure (IOP) at 10 AM at Week 6
Millimeters of mercury (mmHg)Combigan®Timolol Maleate 0.5%
Mean Intraocular Pressure (IOP) at 10 AM at Week 615.9 ± 3.1016.7 ± 2.78
PrimaryMean Intraocular Pressure (IOP) at 10 AM at Week 12

Mean IOP at 10 AM at week 12. IOP is a measurement of the fluid pressure in the eye.

Time frame:
Week 12
Reported as:
Mean · Millimeters of mercury (mmHg)
Mean Intraocular Pressure (IOP) at 10 AM at Week 12
Millimeters of mercury (mmHg)Combigan®Timolol Maleate 0.5%
Mean Intraocular Pressure (IOP) at 10 AM at Week 1215.1 ± 2.5916.9 ± 2.46
SecondaryMean Intraocular Pressure (IOP) at 8 AM at Week 12

Mean IOP at 8 AM at week 12. IOP is a measurement of the fluid pressure inside the eye.

Time frame:
Week 12
Reported as:
Mean · Millimeters of mercury (mmHg)
Mean Intraocular Pressure (IOP) at 8 AM at Week 12
Millimeters of mercury (mmHg)Combigan®Timolol Maleate 0.5%
Mean Intraocular Pressure (IOP) at 8 AM at Week 1217.0 ± 2.5517.7 ± 2.58
SecondaryMean Intraocular Pressure (IOP) at 8 AM at Week 6

Mean IOP at 8 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.

Time frame:
Week 6
Reported as:
Mean · Millimeters of mercury (mmHg)
Mean Intraocular Pressure (IOP) at 8 AM at Week 6
Millimeters of mercury (mmHg)Combigan®Timolol Maleate 0.5%
Mean Intraocular Pressure (IOP) at 8 AM at Week 617.3 ± 2.8717.8 ± 3.17
SecondaryNumber of Subjects With Adverse Events

Number of subjects with adverse events, defined as any untoward medical occurrence in a subject, during the study (reported through the week 12 visit).

Time frame:
Week 12
Reported as:
Number · Participants
Number of Subjects With Adverse Events
ParticipantsCombigan®Timolol Maleate 0.5%
Number of Subjects With Adverse Events1513

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combigan®—0/102 (0%)0/102 (0%)
Timolol Maleate 0.5%—2/102 (2%)0/102 (0%)
Most frequent serious events
Most frequent serious events
EventCombigan®Timolol Maleate 0.5%
Acute exacerbation of COPDRespiratory, thoracic and mediastinal disorders0/1021/102
Bacterial bronchitisInfections and infestations0/1021/102

Baseline characteristics

Age, Continuous
Age, Continuous(years)Combigan®Timolol Maleate 0.5%Total
Median64.5 (30.1 to 87.0)65.9 (29.8 to 88.9)65.4 (29.8 to 88.9)
Sex: Female, Male
Sex: Female, Male(Participants)Combigan®Timolol Maleate 0.5%Total
Female5745102
Male4557102
08

Study locations

2 sites
  • Newark, New Jersey, United States
  • Montreal, Quebec, Canada
09

References and documents

Publications

  • Fechtner RD, Harasymowycz P, Nixon DR, Vold SD, Zaman F, Williams JM, Hollander DA. Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost. Clin Ophthalmol. 2011;5:945-53. doi: 10.2147/OPTH.S19999. Epub 2011 Jul 8. PubMed 21792284 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2008
First posted
Aug 15, 2008
Start
Jul 2008
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Nov 24, 2011
Last update
Apr 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00735449
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Aug 15, 2008
Start date
Jul 2008
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Nov 24, 2011
Last update
Apr 23, 2019

Study contacts

Medical Director
study director · Allergan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Timolol

Start the discussion